18FFDG PET/CT对淋巴瘤骨髓浸润的诊断及预后评估

国际肿瘤学杂志››2016,Vol. 43››Issue (5): 395-397.doi:10.3760/cma.j.issn.1673-422X.2016.05.020

18FFDG PET/CT对淋巴瘤骨髓浸润的诊断及预后评估

岳进,苏丽萍

030001 太原，山西医科大学研究生学院（岳进）；山西医科大学附属肿瘤医院血液科（苏丽萍）

出版日期:2016-05-08发布日期:2016-04-07
通讯作者:苏丽萍 E-mail:sulp2005@sohu.com
基金资助:

山西省卫生厅科技攻关计划（2011044）

Diagnosis and prognosis evaluation of 18FFDG PET/CT in bone marrow infiltration of lymphoma

Yue Jin, Su Liping

Graduate School, Shanxi Medical University, Taiyuan 030001, China

Online:2016-05-08Published:2016-04-07
Contact:Su Liping E-mail:sulp2005@sohu.com

摘要/Abstract

摘要：氟代脱氧葡萄糖正电子发射体层摄影术/计算机体层摄影术（18FFDG PET/CT）与骨髓活检（BMB）对于淋巴瘤骨髓浸润(BMI)的检测具有较高一致性。18FFDG PET/CT对霍奇金淋巴瘤（HL）及侵袭性非霍奇金淋巴瘤(NHL)BMI的敏感性较高，而对惰性NHL敏感性较低。由于18FFDG PET/CT可能出现假阳性或假阴性，因此并不能代替常规BMB。在18FFDG PET/CT引导下进行BMB，可以大大提高BMI的检出率。

关键词:淋巴瘤,骨髓,活组织检查,氟脱氧葡萄糖F18,体层摄影术,螺旋计算机,预后

Abstract:18Ffluorodeoxyglucose positron emission tomography/computed tomography (18FFDG PET/CT) and bone marrow biopsy (BMB) have high consistency in the detection of lymphoma bone marrow infiltration (BMI). 18FFDG PET/CT has a high sensitivity to Hodgkin lymphoma (HL) and aggressive nonHodgkin lymphoma (NHL) BMI, while the sensitivity of indolent NHL is low. Since 18FFDG PET/CT may appears false positive or false negative, so it can not replace the conventional BMB. We can carry out a BMB under the guidance of 18FFDG PET/CT, which can greatly improve the detection rate of BMI.

Key words:Lymphoma,Bone marrow,Biopsy,Fluorodeoxyglucose F18,Tomography, spiral computed;,Prognosis

岳进,苏丽萍. 18FFDG PET/CT对淋巴瘤骨髓浸润的诊断及预后评估[J]. 国际肿瘤学杂志, 2016, 43(5): 395-397.

Yue Jin, Su Liping. Diagnosis and prognosis evaluation of 18FFDG PET/CT in bone marrow infiltration of lymphoma[J]. Journal of International Oncology, 2016, 43(5): 395-397.

参考文献

［1］ Berthet L, Cochet A, Kanoun S, et al. In newly diagnosed diffuse large Bcell lymphoma, determination of bone marrow involvement with 18FFDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy［J］. J Nucl Med, 2013, 54(8): 1244-1250. DOI: 10.2967/jnumed.112.114710. ［2］ CortésRomera M, SabatéLlobera A, MercadalVilchez S, et al. Bone marrow evaluation in initial staging of lymphoma: 18FFDG PET/CT versus bone marrow biopsy［J］. Clin Nucl Med, 2014, 39(1): e46-e52. DOI: 10.1097/RLU.0b013e31828e9504. ［3］ ChenLiang TH, MartinSantos T, Jerez A, et al. The role of bone marrow biopsy and FDGPET/CT in identifying bone marrow infiltration in the initial diagnosis of high grade nonHodgkin Bcell lymphoma and Hodgkin lymphoma. Accuracy in a multicenter series of 372 patients［J］. Am J Hematol, 2015, 90(8): 686-690. DOI: 10.1002/ajh.24044. ［4］ etin G, krkolu MA, zkan T, et al. Can positron emission tomography and computed tomography be a substitute for bone marrow biopsy in detection of bone marrow involvement in patients with Hodgkin′s or nonhodgkin′s lymphoma?［J］. Turk J Hematol, 2015, 32(3): 213-219. ［5］ Hong J, Lee Y, Park Y, et al. Role of FDGPET/CT in detecting lymphomatous bone marrow involvement in patients with newly diagnosed diffuse large Bcell lymphoma［J］. Ann Hematol, 2012, 91(5): 687-695. DOI: 10.1007/s0027701113536. ［6］ Lee Y, Hwang KH, Hong J, et al. Usefulness of (18)FFDG PET/CT for the evaluation of bone marrow involvement in patients with HighGrade NonHodgkin′s lymphoma［J］. Nucl Med Mol Imaging, 2012, 46(4): 269-277. DOI: 10.1007/s1313901201539. ［7］ Pakos EE, Fotopoulos AD, Ioannidis JP. 18FFDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a metaanalysis［J］. J Nucl Med, 2005, 46(6): 958-963. ［8］ Chen YK, Yeh CL, Tsui CC, et al. F18 FDG PET for evaluation of bone marrow involvement in nonHodgkin lymphoma: a metaanalysis［J］. Clin Nucl Med, 2011, 36(7): 553-559. DOI: 10.1097/RLU.0b013e318217aeff. ［9］ Mittal BR, Manohar K, Malhotra P, et al. Can fluorodeoxyglucose positron emission tomography/computed tomography avoid negative iliac crest biopsies in evaluation of marrow involvement by lymphoma at time of initial staging?［J］. Leuk Lymphoma, 2011, 52(11): 2111-2116. DOI: 10.3109/10428194.2011.593273. ［10］ Cheng G, Chen W, Chamroonrat W, et al. Biopsy versus FDG PET/CT in the initial evaluation of bone marrow involvement in pediatric lymphoma patients［J］. Eur J Nucl Med Mol Imaging, 2011, 38(8): 1469-1476. DOI: 10.1007/s002590111815z. ［11］ Adams HJ, Kwee TC, Fijnheer R, et al. Bone marrow F18fluoro2deoxyDglucose positron emission tomography/computed tomography cannot replace bone marrow biopsy in diffuse large Bcell lymphoma［J］. Am J Hematol, 2014, 89(7): 726-731. DOI: 10.1002/ajh.23730. ［12］Kim TM, Paeng JC, Chun IK, et al. Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma［J］. Cancer, 2013, 119(6): 1195-1202. DOI: 10.1002/cncr.27855. ［13］Khan AB, Barrington SF, Mikhaeel NG, et al. PETCT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement［J］. Blood, 2013, 122(1): 61-67. DOI: 10.1182/blood201212473389. ［14］Zhou Z, Chen C, Li X, et al. Evaluation of bone marrow involvement in extranodal NK/T cell lymphoma by FDGPET/CT［J］. Ann Hematol, 2015, 94(6): 963-967. DOI: 10.1007/s0027701422894.

[1]	钱晓涛, 石子宜, 胡格, 吴晓维.Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊.局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华.炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[4]	杨琳, 路宁, 温华, 张明鑫, 朱琳.炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[5]	张洁, 范玲, 李杰, 温华, 苏媛媛, 路宁, 张明鑫.原发性胰腺淋巴瘤1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 316-320.
[6]	刘萍萍, 何学芳, 张翼, 杨旭, 张珊珊, 季一飞.原发性脑胶质瘤患者术后复发危险因素及预测模型构建[J]. 国际肿瘤学杂志, 2024, 51(4): 193-197.
[7]	万芳, 杨钢, 李睿, 万启晶.食管癌患者血清miR-497、miR-383水平及临床意义[J]. 国际肿瘤学杂志, 2024, 51(4): 204-209.
[8]	姚益新, 沈煜霖.血清SOCS3、TXNIP水平对肝细胞癌TACE治疗预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 217-222.
[9]	任露, 谢晓丽, 张坤, 王丽娟.双氢青蒿素联合卡非佐米对多发性骨髓瘤细胞活性、增殖、凋亡的影响及机制研究[J]. 国际肿瘤学杂志, 2024, 51(3): 129-136.
[10]	孙维蔚, 姚学敏, 王鹏健, 王静, 贾敬好.基于血液学指标探讨免疫治疗晚期非小细胞肺癌预后因素及列线图构建[J]. 国际肿瘤学杂志, 2024, 51(3): 143-150.
[11]	刘玉兰, 井海燕, 孙静, 宋伟, 沙丹.胃癌免疫治疗疗效预测及预后标志物的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 175-180.
[12]	彭琴, 蔡玉婷, 王伟.KPNA2在肝癌中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 181-185.
[13]	陈波光, 王苏贵, 张永杰.血清胆碱酯酶与炎症标志物在ⅠA~ⅢA期乳腺癌预后中的作用[J]. 国际肿瘤学杂志, 2024, 51(2): 73-82.
[14]	金旭东, 陈忠坚, 毛伟敏.MTAP基因在恶性间皮瘤中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 99-104.
[15]	黄镇, 陈永顺.循环肿瘤DNA在肝细胞癌诊疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(1): 59-64.